Actively Recruiting
Circulating Markers for Ischemic Heart Disease
Led by UConn Health · Updated on 2025-08-12
550
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying two proteins, cleaved caspase-3 and dystrophin, in the blood to see if their levels rise during acute myocardial infarction (heart attack) and if they are higher in those who develop heart failure afterward. These proteins are linked to heart muscle damage and may be detected using laboratory methods. The study aims to understand whether these markers can help identify people at risk of heart failure after a heart attack. The study observes men and women aged 18 and older who have had an acute myocardial infarction, with or without heart failure. A control group of men aged 60 and above without a history of heart attack or heart disease is also included. Researchers measure blood levels of the two proteins using laboratory tests. Heart failure diagnosis may involve imaging tests to assess heart function. The study does not involve interventions but monitors natural changes in these markers. Participants will be followed for up to three years to track hospitalizations for heart attack, stroke, or death. Researchers collect blood samples and clinical data to compare protein levels between those who develop heart failure and those who do not. The study includes monitoring heart function by imaging and clinical assessments. Participants’ health outcomes over time help determine the relationship between the proteins and heart disease progression.
CONDITIONS
Brief Title
Circulating Markers for Ischemic Heart Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 years and older with acute myocardial infarction confirmed by positive cardiac markers (CKMB or troponin), with or without heart failure symptoms
- Heart failure diagnosis can include imaging evidence such as dilated heart, poor contractile function, or Doppler evidence of diastolic dysfunction or elevated filling pressures
- Control group consists of men aged 60 and older without history of myocardial infarction or heart disease
You will not qualify if you...
- Unable to provide informed consent
- Underwent cardiac or non-cardiac surgery within 3 months before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed for levels of circulating markers after acute myocardial infarction and monitored for heart failure development.
Periodic visits depending on clinical assessments
Trial Site Locations
Total: 1 location
1
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Actively Recruiting
Research Team
F
Fahad Shah
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here